Online citations, reference lists, and bibliographies.
← Back to Search

Emerging Immune Checkpoints For Cancer Therapy

X. Li, W. Hu, X. Zheng, Chu Zhang, Peng Du, Zhuojun Zheng, Y. Yang, J. Wu, M. Ji, Jingting Jiang, Changping Wu
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background. Immunotherapy with immune checkpoint inhibitors has emerged as promising treatment modality for cancer based on the success of anti-CTLA-4 and -PD-1/PD-L1 antibodies. LAG-3 and TIM-3 are two new immune checkpoints. The aim of this work is to review the role and application of LAG-3 and TIM-3 for cancer immunotherapy. Material and methods. Literatures were searched and collected in Medline/PubMed. Results. LAG-3 is presented as a CD4 homolog type I transmembrane protein which binds MHC class II molecules. LAG-3 negatively regulates T cell proliferation, homeostasis and function. IMP321 is formed of an extracellular portion of human LAG-3 fused to the Fc fraction of human IgG1 and has shown increased T cell responses and tolerability in phase I studies on advanced renal cell cancer. When combined with paclitaxel, IMP321 has exerted immune enhancement and tumor inhibition with no significant IMP321-related adverse events. TIM-3 belongs to the TIM family and mainly negatively regulates Th1 immunity. The TIM-3/galectin-9 pathway contributes to the suppressive tumor microenvironment. TIM-3 overexpression is associated with poor prognosis in a variety of cancers. Both LAG-3 and TIM-3 are coexpressed with other immune checkpoints. The application of LAG-3 or TIM-3 does play an important role in anti-tumor responses, and maybe better when combing with anti-CTLA-4 and anti-PD-1/L1 antibodies. Conclusions. These two immune checkpoints play crucial roles in cancer development and may be used in future clinical practice of cancer therapy.
This paper references
10.1089/dna.2013.2116
The expression of Tim-3 in peripheral blood of ovarian cancer.
J. Wu (2013)
10.1158/1078-0432.CCR-09-0068
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
C. Brignone (2009)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
10.1089/dna.2013.2306
Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma.
S. Han (2014)
10.1172/JCI45138
Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs.
S. Gupta (2012)
10.1002/eji.200323382
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
C. Workman (2003)
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling.
S. Hannier (1998)
10.1158/0008-5472.CAN-11-1156
Targeting regulatory T cells in cancer.
W. L. Byrne (2011)
10.1111/j.1365-2567.2005.02145.x
The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells
L. Maçon-Lemaître (2005)
10.4049/jimmunol.1002050
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hémon (2011)
MHC class ii signal transduction in human dendritic cells induced by a natural ligand, the LAg-3 protein
S Andreae (2003)
10.1002/EJI.1830250949
CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins
B. Huard (1995)
10.1309/AJCP9Q6OVLVSHTMY
Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.
Xuewei Zhuang (2012)
10.4049/jimmunol.164.11.5583
A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens1
S. El mir (2000)
Development of lupuslike autoimmune diseases by disruption of the PD1 gene encoding an iTiM motifcarrying immunoreceptor
H nishimura (1999)
10.1158/1078-0432.CCR-09-1339
Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma
S. Ansell (2009)
10.1002/eji.200526090
Expression of lymphocyte activation gene 3 (LAG‐3) on B cells is induced by T cells
Malgorzata Kisielow (2005)
10.1158/0008-5472.CAN-05-2728
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.
C. Casati (2006)
10.1016/j.cellbi.2006.11.002
Proliferation of activated CD1d‐restricted NKT cells is down‐modulated by lymphocyte activation gene‐3 signaling via cell cycle arrest in S phase
Hyun-Jung Byun (2007)
A phase i study of iMP 321 and gemcitabine as the front - line therapy in patients with advanced pancreatic adenocarcinoma
A Wang-gillam (2013)
10.1084/jem.20100637
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
J. Fourcade (2010)
intrinsic and extrinsic control of peripheral T - cell tolerance by costimulatory molecules of the CD 28 / B 7 family
H Bour-Jordan (2011)
interactions between PD1 and PD - L 1 promote tolerance by blocking the TCRinduced stop signal
BT Fife (2009)
10.4046/trd.2014.77.3.111
Immunotherapy for Non-Small Cell Lung Cancer
S. H. Yoon (2014)
10.1016/j.gene.2013.03.056
Therapeutic gene modified cell based cancer vaccines.
A. Kozłowska (2013)
10.1371/journal.pone.0053834
Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
Y. Cao (2013)
10.1177/1010428317716628
Analysis of Tim-3 as a therapeutic target in prostate cancer.
Yongrui Piao (2017)
10.1038/bjc.2015.124
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B. Homet Moreno (2015)
10.4161/onci.23849
TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Kaori Sakuishi (2013)
10.1016/J.VACCINE.2006.03.050
A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321.
S. Fougeray (2006)
identification of a human LAG-3 and TIM-3 in cancer therapy
SA Joosten (2007)
10.1038/ni988
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance
Catherine A. Sabatos (2003)
10.1084/jem.20100643
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
Tim-3 and Tim-3 ligand regulates T helper type 1 responses and D ow nl oa de d by [ R ye rs on U ni ve rs ity L
CA Sabatos (2003)
10.1084/JEM.176.2.327
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens
E. Baixeras (1992)
10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5
CTLA‐4 regulates cell cycle progression during a primary immune response
R. Greenwald (2002)
10.1038/415536a
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L. Monney (2002)
10.4049/jimmunol.174.2.688
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1
C. Workman (2005)
10.1084/jem.20100466
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
T. Okazaki (2011)
10.4049/jimmunol.1400557
Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
R. Ferris (2014)
10.1371/journal.pone.0030676
TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
X. Gao (2012)
10.1172/JCI31184
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems.
Joseph F. Grosso (2007)
10.1200/JCO.2014.59.0703
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
R. Motzer (2015)
10.1073/pnas.1003345107
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
J. Matsuzaki (2010)
10.1073/pnas.0702257104
Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4
S. A. Joosten (2007)
10.4049/jimmunol.172.9.5450
Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation In Vivo1
C. Workman (2004)
10.4049/jimmunol.173.11.6806
Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)1
N. Li (2004)
Role of LAg3 in regulatory T cells
CT Huang
10.4049/jimmunol.174.3.1405
Tim-3+ T-bet+ Tumor-Specific Th1 Cells Colocalize with and Inhibit Development and Growth of Murine Neoplasms1
W. Simmons (2005)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
10.1371/journal.pone.0081799
Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
Jing Jiang (2013)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.4049/jimmunol.180.9.5916
Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II1
B. Liang (2008)
10.1093/INTIMM/11.11.1745
The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.
S. Hannier (1999)
10.1002/EJI.1830241246
Lymphocyte‐activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes
B. Huard (1994)
10.1093/annonc/mdt107
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S. Slovin (2013)
Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells.
M. Avice (1999)
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and Downloaded by
C A Sabatos (2003)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1016/J.IMMUNI.2004.08.010
Role of LAG-3 in regulatory T cells.
C. Huang (2004)
10.1007/s10637-012-9866-y
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
A. Wang-Gillam (2012)
10.1038/ni.1790
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
B. Fife (2009)
10.1371/journal.pone.0058006
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
J. Yan (2013)
10.1158/0008-5472.CAN-11-1620
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
10.1158/2159-8290.CD-14-0863
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.
Nicolas J. Llosa (2015)
10.1084/jem.20082429
TIMs: central regulators of immune responses
D. Hafler (2008)
10.1111/j.1600-065X.2011.01011.x
Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 family
Hélène Bour-Jordan (2011)
The MHC class ii ligand lymphocyte activation gene3 is codistributed with CD 8 and CD 3TCR molecules after their engagement by mAb or peptideMHC class i complexes
S Hannier (1999)
10.1038/ni.2035
T cell exhaustion
E. Wherry (2011)
10.1186/1479-5876-12-36
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
L. Lu (2013)
10.1371/journal.pone.0109080
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
Nicholas M. Durham (2014)
10.1016/j.it.2011.05.003
Emerging Tim-3 functions in antimicrobial and tumor immunity.
Kaori Sakuishi (2011)
Central regulators of immune responses
D A Hafler (2008)
10.1016/J.IT.2003.10.001
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.
F. Triebel (2003)
10.1093/neuonc/not110
The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells.
Liangjuan Fang (2013)
10.4049/jimmunol.0903879
LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
C. Camisaschi (2010)
10.4049/jimmunol.1300271
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
S. Goding (2013)
10.1182/BLOOD-2006-04-015164
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.
M. Gandhi (2006)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1089/DNA.2013.2306
Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma.
Han-song (2014)
10.1084/JEM.171.5.1393
LAG-3, a novel lymphocyte activation gene closely related to CD4
F. Triebel (1990)
10.1007/s11033-012-1862-y
T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer
Danian Tong (2012)
10.1007/s40265-014-0305-6
Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
K. Shih (2014)
10.1158/1078-0432.CCR-13-0035
Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
O. Afanasiev (2013)
10.1200/JCO.2009.26.7609
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J. Brahmer (2010)
10.4049/jimmunol.181.11.7660
Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions1
Keiko Nagahara (2008)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1158/1078-0432.CCR-07-5164
Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
K. Sfanos (2008)
10.4049/jimmunol.168.9.4272
Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1
E. Woo (2002)
10.1016/j.coi.2011.12.005
Tim-3, a negative regulator of anti-tumor immunity.
A. C. Anderson (2012)
10.14694/EdBook_AM.2015.35.76
Managing immune checkpoint-blocking antibody side effects.
M. Postow (2015)
10.4049/jimmunol.0800185
LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1
C. Workman (2009)
10.1158/0008-5472.CAN-11-1487
Prospects for TIM3-Targeted Antitumor Immunotherapy.
S. Ngiow (2011)
10.1186/1479-5876-8-71
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
C. Brignone (2010)
10.1056/NEJMoa1302369
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
10.1182/BLOOD-2003-01-0273
MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223).
S. Andreae (2003)
10.1172/JCI59806
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.
Zhi-Zhang Yang (2012)
10.4049/jimmunol.0903478
Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8+ T Cells by Rapid Induction of Multiple Inhibitory Receptors
S. Takamura (2010)
10.1038/ni1271
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C. Zhu (2005)
intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. immunol Rev 2011;241:180–205
H Bour-Jordan (2011)
10.1182/blood-2010-10-310425
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Qing Zhou (2011)
10.1200/JCO.2012.44.6112
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
10.4049/jimmunol.169.10.5392
Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31
C. Workman (2002)
10.1158/1078-0432.CCR-14-0683
Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
C. Ok (2014)
Tim-3 and Tim-3 ligand regulates T helper type 1 responses and 1712
CA Sabatos (2003)
10.1126/science.1148536
Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells
A. Anderson (2007)
10.1158/0008-5472.CAN-11-2637
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
J. Fourcade (2012)
10.1038/SJ.JID.5700616
TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells.
Zoltán Wiener (2007)
10.1172/JCI73639
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
A. Gros (2014)
10.4049/jimmunol.176.5.2808
Regulated Compartmentalization of Programmed Cell Death-1 Discriminates CD4+CD25+ Resting Regulatory T Cells from Activated T Cells1
G. Raimondi (2006)
MHC class ii signal transduction in human dendritic cells induced by a natural ligand , the LAg3 protein ( CD 223 )
S Andreae (2003)
10.1016/S1074-7613(00)80089-8
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
10.1038/nature04444
Restoring function in exhausted CD8 T cells during chronic viral infection
D. Barber (2006)
The MHC class ii ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3- TCR molecules after their engagement by mAb or peptide- MHC class i complexes. int immunol 1999;11:1745–52
S Hannier (1999)
10.4049/jimmunol.0804211
Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1
Joseph F. Grosso (2009)



This paper is referenced by
10.1007/s12672-015-0241-2
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma
A. Hoff (2016)
Uniqueness of Immune-Related Adverse Events in Cancer Patients Treated With Programmed Cell Death Protein 1 / Programmed Death-Ligand 1 Blockade
Ji-qiao Yang (2019)
10.4103/0971-5916.180197
Immune based therapy for melanoma
Robert Ancuceanu (2016)
10.3892/or.2019.7388
Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim-3 and galectin-9, in cervical cancer
L. Zhang (2019)
10.1111/vco.12294
PD‐1 expression by canine T cells and functional effects of PD‐1 blockade
J. Coy (2017)
10.36468/pharmaceutical-sciences.679
A Novel Recombinant Fusion Protein with Soluble PD-1 and TIM-3 Domains Effectively Binds to Cancer Cells
J. Chen (2020)
10.1189/jlb.5RI0116-013RR
Combinatorial approach to cancer immunotherapy: strength in numbers
A. Vilgelm (2016)
10.3390/cancers10010006
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Neus Martínez-Bosch (2018)
10.3390/ijms19113584
From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis
H. Wang (2018)
10.1080/0284186X.2018.1554259
Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment
O. Dahl (2019)
10.21037/TCR.2016.03.04
Potential value of immunoscoring in rectal cancer patients
Bengt Glimelius (2016)
10.18632/oncotarget.16335
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
O. Franzese (2017)
10.4172/2472-016X.1000110
Long-term Survival of Large Cell Neuroendocrine Lung Carcinoma with Bony Metastases: A Case of Immunoprotectivity?
Deborah Paul (2016)
10.1038/s41379-019-0251-7
TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers
M. Moore (2019)
10.1155/2018/4625472
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
Cristina Vâjâitu (2018)
10.1016/j.biopha.2017.10.143
Notch signaling pathway dampens tumor-infiltrating CD8+ T cells activity in patients with colorectal carcinoma.
W. Yu (2018)
10.1080/15384101.2020.1806426
Ferroptosis: a new unexpected chance to treat metastatic melanoma?
Mara Gagliardi (2020)
10.2147/OTT.S177329
Clinicopathological analysis of PD-L2 expression in colorectal cancer
P. Guo (2018)
10.3389/fphar.2019.00726
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
Jiqiao Yang (2019)
10.3892/or.2017.5399
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines.
Toshifumi Doi (2017)
10.1182/ASHEDUCATION-2016.1.528
Checkpoint inhibition in myeloma.
D. Benson (2016)
10.1155/2017/3264217
Advances in Immunotherapy for Melanoma: A Comprehensive Review
C. Rodríguez-Cerdeira (2017)
10.1186/s12935-020-01380-y
SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer
L. Zhang (2020)
10.1038/s41379-019-0433-3
Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia
Jacob Curley (2020)
10.1007/s00262-020-02701-w
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide
Ayman J Oweida (2020)
10.1016/j.bbcan.2020.188483
Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
Olamide T Olaoba (2020)
10.1002/cpt.394
Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
K. Marrone (2016)
Development and characterization of models of resistance to T-DM1
Juliette Sauveur (2016)
10.2174/0929867325666181106114421
Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules.
P. D'arrigo (2018)
10.3109/0284186X.2015.1126350
Any progress in pancreatic cancer?
B. Glimelius (2016)
10.1158/1078-0432.CCR-18-2811
Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination
Shelby Lennon (2019)
10.1016/j.semcancer.2018.04.003
Checkpoints and beyond - Immunotherapy in colorectal cancer.
Tobias Gutting (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar